No 01 2015

Hansa Biopharma has announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

Eva Lindskog succeeds Lone Carlbom, who will return to an operational role after serving as the company’s CEO.

Elicera Therapeutics appoints Johan Liwing as new CEO effective September 1, 2026.

From August 18-24, 2026, patients, physicians, caregivers, and supporters from around the world will embark on a six-day cycling expedition across Iceland with the purpose of accelerating research into multiple myeloma.

Evaxion expands it pipeline of cancer vaccine programs with EVX-05 against the deadly brain cancer glioblastoma.

The first clinical site has been activated in the company’s global Phase IIb EPIMODE trial evaluating lead drug candidate CS1 in pulmonary arterial hypertension (PAH).

The network has researchers from Iceland, Norway, Sweden, Finland and Denmark. “It is absolutely crucial that we work together in the Nordic Region, because this is a rapidly developing scientific field, and when we join forces across the Nordic countries, we can compare ourselves with larger countries such as France, Germany and Italy. The Nordic […]